Publications

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.

Barghout et al. – 2024

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

Cook et al. – 2024

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer

Barghout et al. – 2024

Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer

Ilnytskyy et al. – 2023

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

Meyers et al. – 2023

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade

Navani et al. – 2023

Machine learning for prediction of cutaneous adverse events in patients receiving anti-PD-1 immunotherapy.

Lewinson et al. – 2020

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.

Meyers et al. – 2019

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

Patil et al. – 2024

Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta.

Cheung et al. – 2024

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib

Gibson et al. – 2024

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

Patil et al. – 2024

Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta.

Cheung et al. – 2024

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor Based Systemic Therapy in BRAF-Mutation Positive Non-Small Cell Lung Cancer

Gibson et al. – 2023

World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort

Gibson et al. – 2022

Retrospective Real-World Outcomes for ALK-Rearranged Lung Cancer Patients Receiving ALK-Receptor Tyrosine Kinase Inhibitors

Gibson et al. – 2021

Impact of Asian Ethnicity on Outcome in Metastatic EGFR-Mutant Non-Small Cell Lung Cancer.

Gibson et al. – 2019

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients

Tudor et al. – 2017

Factors Associated With Early Mortality in Non-Small Cell Lung Cancer Patients Following Systemic Anti-Cancer Treatment: A 10-Year Population Based Study

Gibson et al. – 2019

Comparison of Clinical Characteristics and Outcomes in Relapsed versus de novo Metastatic Non-Small Cell Lung Cancer

Gibson et al. – 2019

Associations of objectively-assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors.

D’Silva et al. – 2018

Impact of Number versus Location of Metastases On Survival in Stage IV M1B Non-Small Cell Lung Cancer

Gibson et al. – 2018

Demographic and clinical correlates of accelerometer assessed physical activity and sedentary time in lung cancer survivors

D’Silva et al. – 2018

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada

Elegbede et al. – 2021

Real-World Adherence to Guideline-Recommended Treatment for Small Cell Lung Cancer.

Elegbede et al. – 2020

Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer

Ilnytskyy et al. – 2023

CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients.

Fung et al. – 2021

The prevalence and prognostic significance of estrogen receptor beta expression in non-small cell lung cancer.

Enwere et al. – 2020

Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer.

Suo et al. – 2018

Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC

Petersen et al. – 2017

Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architecture

Lee et al. – 2014

CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer

Otsuka et al. – 2011

The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer

Otsuka et al. – 2008

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.

Stewart et al. – 2024

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices.

Stewart et al. – 2024

What Is Ailing Oncology Clinical Trials? Can We Fix Them?

Mittal et al. – 2024

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices.

Stewart et al. – 2024

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.

Stewart et al. – 2024

What Is Ailing Oncology Clinical Trials? Can We Fix Them?

Mittal et al. – 2024

Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada

Thanh et al. – 2022

Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011

Ko et al. – 2017